AUTION EYE AI-4510 Urine Particle Analysis System

The AUTION EYE AI-4510 Urine Particle Analysis System is an in vitro diagnostic device for comprehensive automated urinalysis, quantifying and qualifying various formed elements in urine. It operates using flow digital imaging technology, where CMOS sensors capture images at multiple focal points for subsequent algorithmic classification and technologist review.

The AUTION EYE AI-4510 Urine Particle Analysis System is an in vitro diagnostic tool designed for the fully automated analysis of particles in urine samples. Its primary function includes the quantitative measurement of red blood cells (RBC), white blood cells (WBC), and squamous epithelial cells (SQEC); semi-quantitative measurement of bacteria (BACT) and crystals (CRYS); and qualitative assessment of elements like white blood cell clumps (WBCC), non-squamous epithelial cells (NSE), various casts (HYAL, NHC), yeast (YST), mucus (MUCS), and sperm (SPRM). The system operates using flow cell digital imaging technology: urine passes through a flow cell, illuminated by a strobe lamp, and three CMOS image sensors capture color images at different focal points, which are then processed by software using a sorting algorithm for automatic particle classification. It can be used standalone or with an AUTION MAX AX-4060 urine chemistry analyzer, requiring trained technologist review and potential reclassification of instrument-generated decisions. Comprehensive performance evaluations validated the AI-4510 system. Precision studies confirmed repeatability, within-laboratory precision, and reproducibility for quantitative analytes (RBC, WBC, SQEC), with coefficients of variation meeting acceptance criteria across tested concentrations. Linearity was established for quantitative elements (e.g., RBCs 5-1,000/µL; WBCs 5-1,000/µL; SQECs 5-180/µL), and limits of detection were determined (e.g., RBC LoD 2.3/µL). The system demonstrated no significant carryover, and potential interferences from substances such as turbidity or high bacterial counts were characterized, defining concentration limits. Method comparison studies against a predicate device (iQ200 System) and manual microscopy showed strong correlation for quantitative analytes (R² > 0.90 generally) and acceptable agreement for semi-quantitative (e.g., BACT sensitivity 76.2%, CRYS PPA 90.5%) and qualitative elements, confirming its suitability for clinical use according to its intended applications.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AI-4510's use of three CMOS image sensors at different focal points improve particle identification and classification accuracy, particularly for overlapping or morphologically ambiguous particles, compared to single-camera systems?; What are the specific image processing techniques and sorting algorithms employed by the AI-4510 for automatic particle classification, and how were these algorithms validated against diverse pathological urine samples to ensure robustness?; Given the detailed interference data (e.g., Trichomonas affecting RBC/WBC counts), what is the system's flagging capability for suspected interferences, and what are the recommended confirmatory procedures beyond manual reclassification?; The method comparison for Bacteria (BACT) against manual microscopy showed 76.2% sensitivity. What are the clinical implications of this performance for detecting bacteriuria, and are there different performance characteristics when compared to urine culture as a gold standard?; How does the AI-4510's automated classification of broad categories like 'non-hyaline casts' (NHC) assist technologists in the subsequent manual sub-classification, and what image features are emphasized by the system to facilitate this detailed review?